Ningbo Menovo Pharmaceutical (SHSE:603538) Adds CN¥359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 48%
Ningbo Menovo Pharmaceutical (SHSE:603538) Adds CN¥359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 48%
This week we saw the Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE:603538) share price climb by 15%. But that cannot eclipse the less-than-impressive returns over the last three years. In fact, the share price is down 49% in the last three years, falling well short of the market return.
本周,我们看到美诺华制药股份有限公司(SHSE:603538)股价上涨了15%。 但这并不能掏掉过去三年收益欠佳的事实。 实际上,股价在过去三年中下跌了49%,远远低于市场回报。
While the stock has risen 15% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.
尽管股票上涨了15%,但远期股东仍处于亏损状态,让我们看看基本面能够告诉我们什么。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
虽然一些人仍然相信有效市场假说,但已经证明市场是过度反应的动态系统,投资者并不总是理性的。一个不完美但简单的方法来考虑公司市场看法的变化是比较每股收益(EPS)的变化和股价的波动。
Ningbo Menovo Pharmaceutical saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.
美诺华制药在过去三年内股价下跌,同时其每股收益也下降,陷入亏损。 由于公司陷入亏损地位,很难将每股收益的变化与股价变化进行比较。 但我们可以说,在这种情况下,预计会看到股价下跌。
The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).
下图显示了EPS随时间变化的情况(点击图像以显示确切值)。
Dive deeper into Ningbo Menovo Pharmaceutical's key metrics by checking this interactive graph of Ningbo Menovo Pharmaceutical's earnings, revenue and cash flow.
通过查看美诺华的盈利、营业收入和现金流的交互图表,深入了解美诺华的关键指标。
A Different Perspective
不同的观点
Investors in Ningbo Menovo Pharmaceutical had a tough year, with a total loss of 32% (including dividends), against a market gain of about 3.3%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Ningbo Menovo Pharmaceutical is showing 1 warning sign in our investment analysis , you should know about...
投资美诺华的投资者度过了艰难的一年,总计亏损了32%(包括分红),而市场增长约为3.3%。然而,请记住,即使是最好的股票有时也会在十二个月的时间里表现不佳。遗憾的是,去年的表现为股东们迎来了一轮糟糕的表现,股东们在过去五年中总共亏损了3%。我们意识到巴伦·罗斯柴尔德曾说过投资者应该在“街上血流成河”时买入,但我们警告投资者应该先确保他们正在购买高质量的企业。尽管值得考虑市场条件对股价的不同影响,但有更重要的其他因素。即使如此,请注意,在我们的投资分析中,美诺华展示了1个警告信号,你应该知道...
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜欢与管理层一起购买股票,那么您可能会喜欢这个公司的免费列表。 (提示:其中许多公司不为人注意且具有吸引力的估值。)
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。